More on REGN
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Revenues | |
| Sanofi collaboration revenue | |
| Other collaboration revenue | 191.3M |
| Technology licensing | |
| Net product sales | 857.47M |
| Contract research and other | |
| Total revenues | 1.22B |
| Expenses | |
| Research and development | 543.05M |
| Selling, general, and administrative | 270.05M |
| Cost of goods sold | 29.9M |
| Total expenses | 857.32M |
| Loss from operations | 362.8M |
| Other income (expense) | |
| Investment income | 3.3M |
| Interest expense | |
| Total other income (expense) | 3.08M |
| Net loss before income tax benefit | 365.88M |
| Income tax benefit | -101.08M |
| Net loss | 264.8M |
| Net loss per share, basic and diluted | |
| Weighted average shares outstanding, basic and diluted | |
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Morgan Stanley | View Related Stories »
- JPMorgan | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
